ECE2017 Oral Communications Diabetes therapy and complications (5 abstracts)
1Department of Endocrinology and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden; 2Department of Emergency and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden; 3Department of Medical and Health Sciences (IMH)/Division of Community, Linköping, Sweden; 4Department of Thoracic and Vascular Surgery, and Department of Medicine and Health Sciences, Linköping University, Linköping, Sweden.
Background: We aim to test whether plasma copeptin (copeptin), the C-terminal fragment of vasopressin, has predictive value of cardiovascular events in patients with type 2 diabetes without previous cardiovascular disease who were treated in primary care.
Methods: We measured copeptin in 697 patients who participated in the epidemiological study CARDIPP (Cardiovascular Risk Factors in Patients with Diabetes a Prospective Study in Primary Care; ClinicalTrials.gov identifier NCT01049737) and who did not have previously known myocardial infarction or stroke. The outcome variable was a composite endpoint consisting of cardiovascular mortality, hospitalization for myocardial infarction and hospitalization for stroke.
Results: During a median follow-up time of almost 7 years, the unadjusted HR per each increment of Copeptin by 1 pmol/l was 3.5 (95% CI 1.77.1, P<0.001) for the primary endpoint. Following adjustments for age, sex, HbA1c, arterial stiffness (PWW) as well as atherosclerosis plaque the adjusted hazard ratio was 2.4 (95% CI 1.15.2, P=0.03).
Conclusions: In primary preventive patients with type 2 diabetes treated in primary care, copeptin predicted a composite outcome of incident cardiovascular events independently of age, sex, HbA1c, arterial stiffness as well as atherosclerosis plaque.